RA Capital Management Bets Another $20 Million On Kala Pharmaceuticals Inc.

Page 2 of 5 – SEC Filing

CUSIP No. 483119103

1

Names of Reporting Persons.

RA Capital Management, LLC

2 Check the Appropriate Box if a Member of a Group (See Instructions)
(a)      ¨
(b)      ¨
3 SEC Use Only
4

Source of Funds (See Instructions):

AF

5

Check if disclosure of legal proceedings is
required pursuant to Items 2(d) or 2(e):

¨

6

Citizenship or Place of Organization.      Massachusetts

 

Number

of Shares

Beneficially

Owned by

Each

Reporting

Person With

7      Sole Voting
Power      0 shares

8      Shared
Voting Power      4,537,478 shares

9      Sole Dispositive
Power      0 shares

10    Shared Dispositive
Power      4,537,478 shares

11

Aggregate Amount Beneficially Owned by Each
Reporting Person

4,537,478 shares

12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)     ¨
13

Percent of Class Represented by Amount in Row
(11)

14.1%1

14

Type of Reporting Person (See Instructions)

IA, OO (Limited Liability Company)

1
The reporting person is the beneficial owner of 4,537,478 shares of
the Issuer’s Common Stock which constitute approximately 14.1% of the class outstanding.
The percentage calculation assumes that there are currently 32,106,674 outstanding shares
of Common Stock of the Issuer, based on the Issuer’s Prospectus as filed with the
Securities and Exchange Commission (“SEC”) on October 3, 2018. 

Follow Kala Pharmaceuticals Inc. (NASDAQ:KALA)